Abeona Therapeutics (ABEO) Long-Term Debt Issuances (2020 - 2024)
Abeona Therapeutics (ABEO) posted quarterly Long-Term Debt Issuances of $20.0 million for Q1 2024, up 47719.05% quarter-over-quarter from -$42000.0 in Q2 2020.
Powered by 
Analysis
Abeona Therapeutics (ABEO) Long-Term Debt Issuances (2020 - 2024) Analysis & Trends
Abeona Therapeutics' Long-Term Debt Issuances history runs 2 years deep, the most recent figure standing at $20.0 million for Q1 2024.
- In Q1 2024, Long-Term Debt Issuances changed N/A year-over-year to $20.0 million; the TTM figure through Dec 2024 stood at $20.0 million (changed N/A YoY), while the FY2024 annual figure was $20.0 million, changed N/A from the prior year.
- Long-Term Debt Issuances for Q1 2024 stood at $20.0 million, up from -$42000.0 in the prior quarter.
- The five-year high for Long-Term Debt Issuances was $20.0 million in Q1 2024, with the low at -$42000.0 in Q2 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Abeona Therapeutics | 342.29 Mn | 195.46 Mn | 7.20 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2024 | 50.15 Mn |
| Mar 31, 2024 | 20.00 Mn |
| Jun 30, 2020 | -42,000.00 |